CRDL 250117 2.50P (CRDL250117P2500) Stock Options, News & Quotes

US OptionsDetailed Quotes

CRDL250117P2500

Watchlist

1.00
0.000.00%

15min DelayClose Dec 31 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

PRISM MarketView Features Q&A With President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx Addressing Patients With Recurrent Pericarditis
GlobeNewswireDec 19, 2024 08:30 ET
Cardiol Therapeutics Analyst Ratings
BenzingaNov 20, 2024 07:01 ET · Ratings
Cardiol Therapeutics' CardiolRx Gains Buy Rating on Positive Phase 2 Results and Strong Financial Position
TipRanksNov 20, 2024 06:20 ET · Ratings
CBD-Based Drug Reduces Pericarditis Pain And Inflammation, Shows New Clinical Study
BenzingaNov 19, 2024 14:24 ET
Cardiol Therapeutics' Presents Phase II MAvERIC-Pilot Clinical Results In Recurrent Pericarditis Presented At The AHA Scientific Sessions 2024; Marked And Rapid Reductions In Both Pericarditis Pain And Inflammation Maintained Throughout The 26-Week Study
BenzingaNov 18, 2024 11:38 ET
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
newsfileNov 18, 2024 11:37 ET

Comments

Jaguar8

Dec 29, 2024 13:13

🟢 Watchlist December 30,2024, Monday.

NOTE!
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Scale out and secure profits. GREED will make losr and get trapped.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
7. I DO NOT give buy or sell advice
8. CH (cash on hand); AH (after hours): RTH (regular trading hours)
9. No buy pressure/momentum- No day trade.
10. Remember, some stocks may get pumped WITHOUT any catalyst this week ...

131

华尔街之蛆

Nov 19, 2024 09:37

$Cardiol Therapeutics (CRDL.US)$ $Cardiol Therapeutics Inc (CRDL.CA)$ Cash not enough for a Phase III trial. They will surely dilute the stock again in the future. Be careful when buying more.

Jaguar8

Nov 18, 2024 10:38

NEWS

$Cardiol Therapeutics (CRDL.US)$
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
Cardiol Therapeutics (NASDAQ: CRDL) reported positive Phase II MAvERIC-Pilot clinical results for CardiolRx™ in treating recurrent pericarditis. The study showed marked improvements in pericarditis pain and inflammation maintained throughout the 26-week study. The trial enrolled 27 participants across eig...

Jaguar8

Oct 10, 2024 08:09

NEWS

$Cardiol Therapeutics (CRDL.US)$
Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares

Jaguar8

Sep 24, 2024 06:52

NEWS

$Cardiol Therapeutics (CRDL.US)$
Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis
Cardiol Therapeutics (NASDAQ: CRDL) announced the completion of target patient enrollment for its Phase II ARCHER trial, evaluating CardiolRx™ in acute myocarditis. The trial, with 100 patients from five countries, aims to assess the safety, tolerability, and impact of CardiolRx™ on myocardial recovery. Primary outcomes include...